FUNDAMENTALS · Fundamentals · US Healthcare

TScan Therapeutics (TCRX) Fundamentals 2026 — Revenue Analysis | SniperIQ

TScan Therapeutics (TCRX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $57M, trading at $0.94 on the NASDAQ. This SniperIQ fundamentals page covers TScan Therapeutics's valuation, profitability (net margin -1360.6%), revenue (

0M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$57M
Net Margin-1360.6%
Revenue (FY25)
0M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is TScan Therapeutics's market cap?

TScan Therapeutics (TCRX) has a market capitalization of approximately $57M, trading at $0.94 on the NASDAQ. Market cap moves with the live share price.

What is TScan Therapeutics's P/E ratio?

TScan Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is TScan Therapeutics?

TScan Therapeutics runs a net profit margin of -1360.6%, a gross margin of 92.4%, and an operating margin of -1408.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does TScan Therapeutics generate?

TScan Therapeutics reported revenue of

0M for fiscal year 2025, with net income of -
30M and earnings per share (EPS) of -1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does TScan Therapeutics pay a dividend?

TScan Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is TScan Therapeutics financially healthy?

TScan Therapeutics carries a debt-to-equity ratio of 0.95x and a current ratio of 6.65x, with a market beta of 1.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TScan Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TScan Therapeutics (TCRX) the key facts are: market cap $57M, revenue

0M, 52-week range 0.825-2.57. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track TScan Therapeutics's full fundamentals live

Get TScan Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Inovio Pharmaceuticals (INO) fundamentals · Boundless Bio (BOLD) fundamentals · Elicio Therapeutics (ELTX) fundamentals · Xilio Therapeutics (XLO) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons